Printer Friendly

Symlin pens to be available for select patients.

The glucose-lowering drug pramlintide will now be available in pens, but only for patients using premeal bolus insulin.

Last month the Food and Drug Administration said Amylin could begin marketing the SymlinPen 60 and the SymlinPen 120 pen-injector devices for administering pramlintide injection, currently sold in vials. The pens were expected to be available by December 2007, the firm said.

Dosing had been an issue with the vials due to confusion with insulin syringes, which are not marked in microgram units. But the SymlinPen 60 delivers fixed doses of 15, 30, 45, or 60 mcg; the SymlinPen 120 delivers only 60- and 120-mcg doses.

The agency also issued a "Not Approvable" letter for those using only basal insulin without concurrent mealtime (bolus) insulin. Supporting data included results from a 16-week, double-blind, placebo-controlled study of 212 patients with type 2 diabetes who used glargine (basal) insulin with or without oral antidiabetic agents, but who did not use premeal insulin (Diabetes Care 2007;30:2794-9).

In those completing the study, hemoglobin [A.sub.1c] reductions from baseline were greater in the 87 on pramlintide (7.8%, from 8.5%), compared with the 91 on placebo (8.1%, from 8.5%), said Dr. Matthew Riddle, of Oregon Health and Science University, Portland, and associates.

An FDA spokeswoman said the agency does not discuss its nonapprovable actions.
COPYRIGHT 2007 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Endocrinology
Author:Tucker, Miriam E.
Publication:Internal Medicine News
Article Type:Brief article
Geographic Code:1USA
Date:Dec 1, 2007
Words:223
Previous Article:Asthma diagnosis and management.
Next Article:Potency specifications tightened for levothyroxine.
Topics:


Related Articles
FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use.
Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters